874 - Reviewing the recurrence rates in Stage I-III HR or ER positive breast cancer in obese patients given multi-modal weight loss plan post-treatment with Aromatase Inhibitors

Aromatase inhibitors (AIs) in the treatment of endocrine receptor positive breast cancer  stages I-III, poses significant challenges in the management of obesity. Obesity is associated with an increased risk of breast cancer incidence and higher rates of cancer recurrence. Moreover, the use of AIs, while effective in reducing estrogen levels and preventing ER or HR positive breast cancer recurrence, may exacerbate weight gain and metabolic disturbances in obese individuals. Weight management strategies have experienced increased attention in breast cancer survivors in recent years, especially overweight or obese individuals. Novel data makes it possible to infer that obesity management activities that incorporate dietary counseling and physical activity can reduce recurrence rates.

Design:

Participants in this study were individuals with Stage I-III endocrine receptor positive breast cancer who had completed adjuvant therapy and had a BMI in the 40s or 50s, increasing risk of recurrence. Eligible patients were identified based on the start date for endocrine therapy. High-risk patients were then assigned to either the intervention or control group. Those in the intervention group received access to a dietician, along with informational pamphlets on physiology and weight loss strategies. Both intervention and control groups were briefed about the study, with those in the intervention group encouraged to utilize the provided resources for weight management.

Results: The evidence from our study will underscore the potential benefits of multimodal weight loss interventions in overweight or obese breast cancer survivors, particularly in improving anthropometric outcomes and enhancing overall quality of life.

Conclusions:

While the studies included in our analysis demonstrated reductions in body weight, BMI, and waist circumference, as well as improvements in quality of life measures, there remains a notable gap in understanding the impact of these interventions on breast cancer recurrence rates, especially in the context of endocrine-positive breast cancer treated with Aromatase Inhibitors (AIs).